Osteopore stands as a regenerative medtech powerhouse, says RSM Report on Australia Medtech Sector
In the realm of medical technology, where innovation meets necessity, Osteopore International stands as a beacon of progress in the field of tissue regeneration. Osteopore International was born when the company’s founding members, three scientists, and three surgeons, wanted to scientifically engineer better solutions to help patients regrow bone. Today, it stands as a regenerative medtech powerhouse that designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopaedic and maxillofacial surgery use.
The regenerative medicine journey of Osteopore International is now showcased in the latest RSM Australia industry report titled 'The Future of MedTech in Australia.' This report offers valuable insights into the continually evolving medical technology landscape.
Australia is poised to be a leader in the rapidly growing MedTech sector. In the report, our CEO, Dr Yujing Lim, highlights our pivotal role in regenerative medicine – creating biomimetic and bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery across 25 countries.
Leveraging 3D printing technology, we've now created more than 100,000 global implants, demonstrating our commitment to meaningful patient outcomes despite the global challenges facing the MedTech sector. Dr Lim emphasises our dedication to overcoming the hurdles to market adoption via proactive education and engagement with healthcare professionals.
“….We want to continue to collaborate with companies in Australia, support the ecosystem and accelerate the commercialisation pathway for everyone” says Dr Lim.
Download the full report to have a closer look at RSM's case study on Osteopore’s journey and its bright future as a regenerative medicine leader contributing to the Australian MedTech sector.